404 related articles for article (PubMed ID: 27535663)
1. Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery.
Green MM; Chao N; Chhabra S; Corbet K; Gasparetto C; Horwitz A; Li Z; Venkata JK; Long G; Mims A; Rizzieri D; Sarantopoulos S; Stuart R; Sung AD; Sullivan KM; Costa L; Horwitz M; Kang Y
J Hematol Oncol; 2016 Aug; 9(1):71. PubMed ID: 27535663
[TBL] [Abstract][Full Text] [Related]
2. Influence of a dual-injection regimen, plerixafor and CXCR4 on in utero hematopoietic stem cell transplantation and engraftment with use of the sheep model.
Goodrich AD; Varain NM; Jeanblanc CM; Colon DM; Kim J; Zanjani ED; Hematti P
Cytotherapy; 2014 Sep; 16(9):1280-93. PubMed ID: 25108653
[TBL] [Abstract][Full Text] [Related]
3. Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study.
Cohen S; Roy J; Lachance S; Delisle JS; Marinier A; Busque L; Roy DC; Barabé F; Ahmad I; Bambace N; Bernard L; Kiss T; Bouchard P; Caudrelier P; Landais S; Larochelle F; Chagraoui J; Lehnertz B; Corneau S; Tomellini E; van Kampen JJA; Cornelissen JJ; Dumont-Lagacé M; Tanguay M; Li Q; Lemieux S; Zandstra PW; Sauvageau G
Lancet Haematol; 2020 Feb; 7(2):e134-e145. PubMed ID: 31704264
[TBL] [Abstract][Full Text] [Related]
4. Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells.
Cieri N; Greco R; Crucitti L; Morelli M; Giglio F; Levati G; Assanelli A; Carrabba MG; Bellio L; Milani R; Lorentino F; Stanghellini MT; De Freitas T; Marktel S; Bernardi M; Corti C; Vago L; Bonini C; Ciceri F; Peccatori J
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1506-14. PubMed ID: 26001696
[TBL] [Abstract][Full Text] [Related]
5. A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.
Koreth J; Kim HT; Lange PB; Bindra B; Reynolds CG; Chammas MJ; Armand P; Cutler CS; Ho VT; Glotzbecker B; Nikiforow S; Ritz J; Blazar BR; Soiffer RJ; Antin JH; Alyea EP
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1907-13. PubMed ID: 26055298
[TBL] [Abstract][Full Text] [Related]
6. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
8. Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells.
Chen YB; Le-Rademacher J; Brazauskas R; Kiefer DM; Hamadani M; DiPersio JF; Litzow MR; Craig M; Horwitz ME; Artz AS; McClune BL; Fernandez HF; Duong HK; Kobusingye H; Proue M; Drexler RJ; Horowitz MM; Shaw BE; Miller JP; Hosoba S; Waller EK; Devine SM
Blood Adv; 2019 Mar; 3(6):875-883. PubMed ID: 30890544
[TBL] [Abstract][Full Text] [Related]
9. Single infusion of donor mononuclear early apoptotic cells as prophylaxis for graft-versus-host disease in myeloablative HLA-matched allogeneic bone marrow transplantation: a phase I/IIa clinical trial.
Mevorach D; Zuckerman T; Reiner I; Shimoni A; Samuel S; Nagler A; Rowe JM; Or R
Biol Blood Marrow Transplant; 2014 Jan; 20(1):58-65. PubMed ID: 24140121
[TBL] [Abstract][Full Text] [Related]
10. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction.
Devine SM; Vij R; Rettig M; Todt L; McGlauchlen K; Fisher N; Devine H; Link DC; Calandra G; Bridger G; Westervelt P; Dipersio JF
Blood; 2008 Aug; 112(4):990-8. PubMed ID: 18426988
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 study of plerixafor in combination with total body irradiation-based myeloablative conditioning for allogeneic hematopoietic stem cell transplantation.
Mori T; Kikuchi T; Yamazaki R; Koda Y; Saburi M; Sakurai M; Shigematsu N; Okamoto S; Kato J
Int J Hematol; 2021 Jun; 113(6):877-883. PubMed ID: 33644841
[TBL] [Abstract][Full Text] [Related]
12. Plerixafor (Mozobil) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantation.
Flomenberg N; Comenzo RL; Badel K; Calandra G
Biol Blood Marrow Transplant; 2010 May; 16(5):695-700. PubMed ID: 20067838
[TBL] [Abstract][Full Text] [Related]
13. Day +100 Platelet Count Predicts Survival After Allogeneic Hematopoietic Stem-Cell Transplantation in Children With Hematologic Malignancies.
Moneib H; Hafez H; Abdalla A; Hassanain O; Lehmann L; Haddad AE
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):e221-e227. PubMed ID: 30846344
[TBL] [Abstract][Full Text] [Related]
14. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
15. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
Le Bourgeois A; Mohr C; Guillaume T; Delaunay J; Malard F; Loirat M; Peterlin P; Blin N; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Lode L; Bene MC; Chevallier P
Biol Blood Marrow Transplant; 2013 Jun; 19(6):934-9. PubMed ID: 23523970
[TBL] [Abstract][Full Text] [Related]
16. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
[TBL] [Abstract][Full Text] [Related]
17. Filgrastim-Stimulated Bone Marrow Compared with Filgrastim-Mobilized Peripheral Blood in Myeloablative Sibling Allografting for Patients with Hematologic Malignancies: A Randomized Canadian Blood and Marrow Transplant Group Study.
Couban S; Aljurf M; Lachance S; Walker I; Toze C; Rubinger M; Lipton JH; Lee SJ; Szer J; Doocey R; Lewis ID; Huebsch L; Howson-Jan K; Lalancette M; Almohareb F; Chaudhri N; Ivison S; Broady R; Levings M; Fairclough D; Devins G; Szwajcer D; Foley R; Smith C; Panzarella T; Kerr H; Kariminia A; Schultz KR
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1410-1415. PubMed ID: 27154847
[TBL] [Abstract][Full Text] [Related]
18. Effect of high-dose plerixafor on CD34
Pantin J; Purev E; Tian X; Cook L; Donohue-Jerussi T; Cho E; Reger R; Hsieh M; Khuu H; Calandra G; Geller NL; Childs RW
Haematologica; 2017 Mar; 102(3):600-609. PubMed ID: 27846612
[TBL] [Abstract][Full Text] [Related]
19. Partial engraftment following plerixafor rescue after failed sibling donor peripheral blood stem cell harvest.
Eyre TA; King AJ; Peniket A; Rocha V; Collins GP; Pawson R
Transfusion; 2014 May; 54(5):1231-4. PubMed ID: 24117899
[TBL] [Abstract][Full Text] [Related]
20. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
Steinberg M; Silva M
Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
